Auristatin E is widely used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It functions as a potent cytotoxic agent that inhibits cell division by disrupting microtubule dynamics. When conjugated to monoclonal antibodies, it selectively delivers its toxic effects to cancer cells, minimizing damage to healthy tissues. This approach enhances the precision and efficacy of cancer treatments, particularly in treating hematological malignancies and solid tumors. Its high potency makes it a key component in advancing personalized medicine and improving therapeutic outcomes in oncology.